Plasmids are powerful tools utilized in various bioprocesses, from recombinant proteins and vaccines to gene therapy applications such as AAV production. In manufacturing, current regulatory authorities (WHO, EMA, US FDA) require a validated process to measure the amount of residual DNA, including residual plasmid DNA, and prove that it is below accepted limits in the final drug substance.
Currently the preferred method of residual plasmid quantitation is performed by home-brewed real-time PCR, which requires a lengthy development process and often chain-of-custody issues of reagents and standards.
In this presentation we share the development and validation of a highly sensitive, off-the-shelf solution for the detection of residual kanamycin-resistance plasmid DNA designed to meet regulatory requirements.
In this webinar you’ll learn: